A Phase 1/2 interventional study of umbilical cord mesenchymal stem cells in Pathologic Processes, sponsored by Meribank Biotech Co., Ltd.. Active, not recruiting at 2 sites in Taiwan. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-07-15.
Sponsored by Meribank Biotech Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Frailty with a site in Taiwan — 23 open to participants now, 24 under way, none of them phase 3. Frailty · Taiwan.
Among the 68 studies in Frailty with a site in Taiwan, this one is the 39th largest by enrollment of the 54 interventional ones that give a count, is one of 7 that started in 2024, is the only one in phase 1/2, reaches primary completion later than 13 of the 23 other live ones, and was the 45th registered.
1,287 studies on the registry are indexed under Frailty; 454 are open to participants now.
Browse Frailty studies →23 of the 68 studies in Frailty with a site in Taiwan are open now. Recruiting first, the newest first:
Taipei Medical University · Sites in Taiwan
Ages 65+
Chang Gung University of Science and Technology · Sites in Taiwan
Ages 60+
National Health Research Institutes, Taiwan · Sites in Taiwan
Ages 40+ · Healthy volunteers
China Medical University Hospital · Sites in Taiwan
Ages 20+
Tainan Hospital, Ministry of Health and Welfare · Sites in Taiwan
Ages 50+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 301 Frailty studies recruiting now, 236 (78%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 67 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2
First in 2008; this study’s year is marked. 7 started in 2024.
This study's enrollment of 66 is below the median of 82 across 769 interventional studies indexed under Frailty.
Median enrollment 94 across the 54 interventional studies, 151 across the 14 observational. Of the 33 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 68 have an industry lead sponsor. The 10 most frequent:
Meribank Biotech Co., Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Meribank Biotech Co., Ltd. has 1 study filed under Frailty — fewer than ten, so there is no comparison to draw.
7 of the studies in Frailty with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06501066Meribank Biotech Co., Ltd.Mesenchymal Stem Cells for Frailty Syndrome | 2026-12 |
| NCT06671353National Taiwan University HospitalVideo Decision Support for Advance Care Planning in Geriatric Patients With Frailty | 2026-12-01 |
| NCT07815158National Yang Ming Chiao Tung UniversityMulti-Component Nutrition, Intrinsic Capacity, and Physical Function in Older Adults | 2026-12-15 |
| NCT07136935China Medical University HospitalA Multicenter Observational Study of an Integrated Traditional Chinese and Western Medicine Care Model in Post-Acute Treatment of Frail Elderly Patients | 2026-12-31 |
| NCT07068308National Yang Ming Chiao Tung UniversityEffects of a Wed-based FRAIL-SM Program Among Patients With Heart Failure | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 68 studies in Frailty with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase I/II study is designed to evaluate the efficacy and safety of UMC119-06-05, an allogeneic umbilical cord mesenchymal stem cells, in older adults with frailty syndrome. This study will also seek to determine the long-term safety and clinical outcomes of UMC119-06-05 in subjects with frailty syndrome, which will provide information for subsequent clinical trials with UMC119-06-05.
Frailty is a disorder of several inter-related physiological systems, including genetic and environmental factors in combination with epigenetic mechanisms, which regulate the differential expression of genes in cells and could be especially important in ageing. Frailty syndrome characterized by a progressive decline in health and clinical symptoms of exhaustion, weight loss, a feeling of slowing down, and a decrease in functional capacity. Current interventions focus on interdisciplinary approaches which include nutritional supplementation, physical exercise, and cognitive intervention. The lack of standardized treatment of the disease resulted in the increasing number of elders diagnosed with frailty. Therefore, development of new therapeutic modalities to improve the clinical outcomes and prognosis of frailty syndrome in adult patients is of urgent need. Recently, preclinical and clinical studies support a cell-based, regenerative treatment strategy i.e., allogenic umbilical cord mesenchymal stem cell therapy may represent a novel therapy for aging frailty. This clinical trial is a phase I/II study. Phase I is an open-label study and all eligible subjects will receive a single-dose IV infusion of UMC119-06-05. Phase II study is a randomized, placebo-controlled, single-blind study and half of eligible subjects will receive a single-dose IV infusion of UMC119-06-05, the others will receive placebo.
1,287 studies on the registry are indexed under Frailty; 454 are open to participants now.
This study's enrollment of 66 is below the median of 82 across 769 interventional studies indexed under Frailty.
Browse Frailty studies →Meribank Biotech Co., Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Compared within Frailty, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pathologic Processes. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects will be eligible for enrollment in the study only if they meet ALL of the following criteria:
Exclusion Criteria:
Subjects will be eligible for enrollment in the study only if they meet NONE of the following criteria:
Subjects who have a significant comorbid medical condition(s), as judged by the investigator, including, but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
umbilical cord mesenchymal stem cells, 100×10\^6 cells/subject, single treatment by intravenous infusion in phase I.
Biological: umbilical cord mesenchymal stem cells
umbilical cord mesenchymal stem cells, 100×10\^6 cells/subject, single treatment by intravenous infusion in phase II.
Biological: umbilical cord mesenchymal stem cells
Peripheral IV infusion of placebo at baseline.
Biological: umbilical cord mesenchymal stem cells
Patients assigned to UC-MSC administration groups will receive one administrations
Incidence of Treatment-Emergent Adverse Events (TEAEs)/ Serious Adverse Events (SAEs).
Phase I : Incidence of any treatment-emergent serious adverse events (SAE), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities.
Time frame: Up to 12 months through study
Incidence of withdrawals due to adverse events
Phase I: Incidence of any treatment-emergent serious adverse events (SAE), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities.
Time frame: Up to 12 months through study
vital signs
Phase I: change in vital signs
Time frame: Up to 12 months through study
physical examination
Phase I: change in physical examination
Time frame: Up to 12 months through study
clinical laboratory test results
Phase I: change in clinical laboratory test results
Time frame: Up to 12 months through study
electrocardiogram
Phase I: change in electrocardiogram
Time frame: Up to 12 months through study
Mean change from baseline in frailty status (Cardiovascular Health Study [CHS] frailty score
CHS scale consists of five components-unintentional weight loss, exhaustion, low activity, weakness, and slowness
Time frame: change from baseline to Day 91, Day 181, and Day 361
Mean change from baseline in grip strength
Hand grip strength as assessed by a dynamometer. Grip strength is recorded (in mmHg) three times for each hand.
Time frame: change from baseline to Day 91, Day 181, and Day 361
Mean change from baseline in chair-stand test
a subject is able to transfer from a seated to a standing position and back to sitting five times
Time frame: change from baseline to Day 91, Day 181, and Day 361
Mean change from baseline in muscle mass and bone density
muscle mass and bone density will be measured using DXA
Time frame: change from baseline to Day 91, Day 181, and Day 361
Mean change from baseline in quality of life measured by change in SF-12
a quality of life measure
Time frame: change from baseline to Day 91, Day 181, and Day 361
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Solizmestrocel
Meribank Biotech Co., Ltd.